iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 3,750 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 3,750 shares of iRadimed stock in a transaction on Monday, May 4th. The shares were sold at an average price of $85.69, for a total transaction of $321,337.50. Following the completion of the transaction, the chief executive officer directly owned 2,191,250 shares of the company’s stock, valued at $187,768,212.50. The trade was a 0.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Performance

IRMD opened at $86.24 on Thursday. iRadimed Corporation has a fifty-two week low of $50.61 and a fifty-two week high of $107.90. The company has a fifty day moving average of $96.04 and a two-hundred day moving average of $94.33. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of 47.13 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The company had revenue of $21.98 million during the quarter, compared to analysts’ expectations of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities research analysts forecast that iRadimed Corporation will post 1.94 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s payout ratio is currently 43.72%.

Institutional Trading of iRadimed

A number of institutional investors and hedge funds have recently modified their holdings of IRMD. Vanguard Group Inc. grew its stake in iRadimed by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock valued at $40,313,000 after acquiring an additional 5,475 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after acquiring an additional 205,783 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in iRadimed by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 217,129 shares of the medical equipment provider’s stock valued at $21,123,000 after acquiring an additional 2,578 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in iRadimed by 37.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after acquiring an additional 55,426 shares in the last quarter. Finally, State Street Corp grew its stake in iRadimed by 3.1% during the 4th quarter. State Street Corp now owns 192,952 shares of the medical equipment provider’s stock valued at $18,770,000 after acquiring an additional 5,713 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Lake Street Capital reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Finally, Roth Mkm reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.